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Abstract
The epidermal growth factor receptor variant III (EGFRvIII) is the most common variation of EGFR.
Because it shows a high frequency in several different types of tumor and has not been detected in
normal tissues, it is an ideal target for tumor specific therapy. In this study, we prepared EGFRvIII-
HBcAg fusion protein. After immunization with fusion protein, HBcAg or PBS, the titers of
antibody in BALB/c mice immunized with fusion protein reached 2.75 × 105. Western blot analysis
demonstrated that the fusion protein had specific antigenicity against anti-EGFRvIII antibody.
Further observation showed fusion protein induced a high frequency of IFN-g-secreting
lymphocytes. CD4+T cells rather than CD8+T cells were associated with the production of
IFN-g. Using Renca-vIII(+) cell as specific stimulator, we observed remarkable cytotoxic activity in
splenocytes from mice immunized with fusion protein. Mice were challenged with Renca-vIII(+)
cells after five times immunization. In fusion protein group, three of ten mice failed to develop
tumor and all survived at the end of the research. The weight of tumors in fusion protein were
obviously lighter than that in other two groups (t = 4.73, P = 0.044;t = 6.89, P = 0.040). These
findings demonstrated that EGFRvIII-HBcAg fusion protein triggered protective responses against
tumor expressing EGFRvIII.
Introduction
Epidermal growth factor receptor (EGFR) plays an
important role in tumor cell proliferation, differentia-
tion and survival. Increasing evidences suggest that
alterations within the EGFR gene may be as important
as EGFR-overexpression to induce oncogenic effects
[1-3]. The most common variation is an in-frame
deletion of exons 2-7 in the mRNA, resulting in a
truncated mutant (epidermal growth factor receptor
variant III, EGFRvIII). Even though EGFRvIII is lack of
a portion of extracellular ligand-binding domain and can
not bind to its ligand, the tyrosine kinase in the
intracellular portion can be constitutively activated,
thereby leading to receptor dimerization, autophosphor-
ylation and stimulation of signal transduction cascades
[4]. Because EGFRvIII is present with a high frequency in
several different types of tumor and has not been
detected in normal tissues, it is an ideal target for
tumor specific therapy[5,6]. Among approaches directed
to EGFRvIII, vaccine is a promising strategy.
Recombinant protein has been intensively studied as a
vaccine on the basis of genetic engineering technology.
Compared with peptide vaccine, recombinant protein
has many advantages such as easy manipulation, mass
production and low cost. The carrier of foreign epitope is
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important for construction of recombinant protein.
Hepatitis B core protein (HBcAg) is one of the most
promising delivery vehicles for its high-density, immu-
nogenic presentation of foreign epitope and its produc-
tion in various expression systems[7]. The e1 loop in the
main determinant of the core antigen is considered as
the most promising insertion site[8].
Pep-3, a 13-amino-acid peptide corresponding to the
amino acid sequence of the EGFRvIII fusion junction
(LEEKKGNYVVTDH), is an immunogenic peptide that
was firstly reported by Moscatello[9]. In this study,
foreign epitope, encoding Pep-3, was inserted into the
immunodominant e1 loop of the HBcAg to prepare the
recombinant fusion protein. Next, the antigenicity and
immunogenicity of the fusion protein were detected in
vitro. The protective immune responses against tumor
was evaluated in a murine model.
Materials and methods
Construction of recombinant expression plasmids
The genes encoding Pep-3, HBcAg amino acid resides
from 1 to 71 and from 89 to 144 were amplified by PCR,
and a set of primers were listed in Table 1.
Recombinant prokaryotic expression plasmid Pep3-
HBcAg/pET-28a(+) was constructed(Figure 1), and then
identified by restriction enzymes and sequencing.
Expression and purification of the fusion protein in
Escherichia coli
Recombinant plasmid Pep3-HBcAg/pET-28a(+) was
introduced into Escherichia coli BL21 (DE3). Then
isopropy-b-D-thiogalactoside (IPTG, Sigma) was added
to induce fusion protein expression. The BL21 cells were
harvested, supernatant and sediment were subjected for
SDS-PAGE. As the fusion protein was confirmed to be
present in inclusion bodies, a further lysis step was
performed (8 M urea overnight). The supernatant was
purified on a Ni2+-NTA affinity chromatography column
(Novagen). The His-tag was removed and the concentra-
tion of purified fusion protein was measured with the
Bradford assay. EGFRvIII-specific antibody (Zymed) was
used to confirm the identity of the fusion protein.
Immunization of mice and antibody detection
Thirty 6-8-week-old female BALB/c mice were purchased
from Medical Experimental Animal Center, Xi’an Jiao-
tong University. All studies were performed in accor-
dance with the Institutional Animal Care and Use
Committee (IACUC) of Xi’an Jiaotong University. Ten
mice were subcutaneously injected with fusion protein
(100 μg/animal) emulsified in Freund’s complete adju-
vant (Sigma) on day 0 and with the same amount of
protein emulsified in Freund’s incomplete adjuvant on
day 7. The third and following boosters were done
only with fusion protein once a week with a total of
seven immunizations. Other 20 mice were divided into
two groups, and immunized with HBcAg and PBS.
Immune serum samples were collected and stored at
Table 1: Sequence of primers used for PCR amplification














Map of Pep3-HBcAg/pET-28a(+) prokaryotic
expression plasmid. The three DNA fragments were
ligated and subcloned into plasmid pGEMEX-1. Then fusion
gene Pep3-HBcAg was digested with restriction enzymes
EcoRI and SalI and ligated into the equivalent sites of the pET-
28a(+) vector, yielding His-tagged Pep3-HBcAg/pET-28a(+).
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-70°C. Antibody titers were assayed by enzyme-linked
immunosorbent assay (ELISA).
IFN-g detection
Enzyme-linked immunospot assay (ELISPOT) was used
to evaluate tumor-specific IFN-g-secretion in splenocytes.
One week after the final vaccination, spleen cells from
three mice per group were harvested. Immunospot plates
were coated with 100 μl anti-mouse g-IFN monoclonal
antibody (5 μg/ml, BD PharMingen). Freshly isolated
splenocytes were added into plate at a density of 3 × 106
cells/well and co-cultured with 1 μg/ml EGFRvIII-specific
peptide (pep-3) for 20 h at 37°C. Medium without
blood-serum was added as negative control. Plates were
washed and incubated with 50 μl/well of biotin-
conjugated anti-mouse IFN-g, and then stayed overnight
at 4°C. Then, 10 μl/well of HRP-labelled streptavidin was
added. After extensive washing, 100 μl AEC substrate was
added until development of visible spots. Plates were
then washed, air-dried and spots were counted using an
ELISPOT reader (CTL Co.). To reveal roles of CD4+and
CD8+ T cells in the immune response, splenocytes were
depleted of CD4+ or CD8+ T cells by using corresponding
antibody (Miltenyi Biotec Inc.) before ELISPOT assays.
Cytotoxicity assay
Splenocytes were harvested from three mice per group
one week after the final vaccination, and then incubated
with irradiated Renca-vIII(+)cells(EGFRvIII transfected
Renca cells[10]). Five days later, T cells were harvested
and purified from the cultures using lymphocyte
separating buffer. These T cells were used as CTL effector
cells and co-cultured with target cells renca-vIII(+)cells at
various effector/target ratios for 8 h at 37°C. Values were
expressed as the percentages of surviving Renca-vIII(+)
cells cultured with effector cells. Renca cells which were
not transfected with EGFRvIII served as control.
Tumor challenge
Thirty BALB/c mice were divided into three group(10
mice pre group), and immunized with fusion protein,
HBcAg and PBS. After five times of immunization,
antibody titers of mice immunized with fusion protein
reached 2 × 105. Then all mice were challenged with
1.5 × 105 Renca-III(+) cells in the left flank. Tumor
growth was measured and volumes were calculated
according to the formula V = (a2·b2·c2)/6, where V
represents tumor volume and a, b, and c were
perpendicular diameters of the tumor. After observation,
mice were killed, and tumors were weighted.
Statistical analyses
Alldatawereexpressedasmeans±SD.Comparisonsbetween
individual data points were performed by Student’s t-test.
Data for quantitation were evaluated by analysis of variance
(ANOVA). p < 0.05 was considered statistically significant.
Results
Construction of recombinant expression plasmids
The PCR product and recombinant plasmid were
detected by restriction analysis (Figures 2, 3 and 4) and
then sequenced. The results showed that the compound
gene Pep-3, cloning plasmid Pep3-HBcAg/pGEMEX-1,
and expression plasmid Pep3-HBcAg/pET-28a (+) were
successfully constructed.
Expression and purification of the fusion protein
To obtain the fusion protein, the engineering strains E.
coli BL21 (DE3) were cultured in 2 × YT with 0.5%
Figure 2
Identification of PCR product. lane1: PCR product of
Pep-3; lane2: DNA Marker of 200 bp.
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glucose and induced by IPTG at the concentration of
1 mM for 6 h. SDS-PAGE analysis demonstrated that
recombinant fusion protein was efficiently and inducibly
expressed in inclusion body form and could dissolve in
6 M urea. The molecular weight of the fusion protein
was shown to be approximately 15.4 kD as expected.
According to the results of SDS-PAGE and gel image
analysis, the purified fusion protein accounted 92% of
totle protein (Figure 5). Western blot analysis demon-
strated that the fusion protein had specific antigenicity
against anti-EGFRvIII antibody (Figure 6).
Immunization assay of fusion protein
To investigate whether the EGFRvIII-HBcAg fusion
protein could induce humoral immune response, the
tail vein serum samples were collected on day 0, 14, 21,
28, 35, 42 and 48, and the antibody titers against the
fusion protein were tested by ELISA (Figure 7).
Induction of specific CTL response
ELISPOT assay was carried out to determine the
frequency of lymphocytes secreting IFN-g. The number
of IFN-g secreting cells was very low in mice immunized
with HBcAg or PBS alone, whereas vaccination with
fusion protein induced a high frequency of IFN-g-
secreting cells (p < 0.05) (Figure 8). To identify which
cell populations were involved in the IFN-g production,
the CD4- or CD8-depleted splenocytes from mice
immunized with fusion protein were detected. The
depletion of CD4+ T cells could completely abrogate
IFN-g production by the harvested splenocytes, but the
depletion of CD8+T cells had no influence on the
number of ELISPOTs (Figure 9). This finding suggest that
CD4+ T cells, but not CD8+ T cells, play an important
role in anti-tumor activity of fusion protein.
Furthermore, the cytotoxic activity of splenocytes from
mice was examined (Figure 10, 11). Using Renca-vIII(+)
cells as specific stimulator in vitro, cytotoxic activity
against Renca-vIII(+) cells was observed in splenocytes
from mice immunized with fusion protein, whereas
there was no obvious killing activity in splenocytes from
mice that received HBcAg or PBS (p < 0.001). Using
Renca cells without EGFRvIII transfection as stimulator,
no obvious cytotoxic activity was observed in the three
groups.
Figure 3
Identification of plasmid Pep3-HBcAg/pGEMEX-1.
lane1: cloning plasmid Pep3-HBcAg/pGEMEX-1 digested with
EcoR I and XhoI; lane 2: pep3-HBcAg/pGEMEX-1 plasmid
without digestion; lane 3:lDNA/HindIII marker(23.13 Kb,
9.414 Kb, 6.557 Kb, 4.371 Kb, 2.082 Kb, 0.564 Kb,
0.125 Kb); lanel 4: 100 bp DNA Ladder.
Figure 4
Identification of plasmid pep3-HBcAg/pET-28a (+).
Lanel1: lDNA/HindIII marker; lanel 2: 100 bp DNA Ladder;
lane 3: recombinant expression plasmid pep3-HBcAg/pET-
28a (+) digested with EcoR I and SalI; lane 4: pep3-HBcAg/
pET28a (+) plasmid without digestion.
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Protective antitumor activity
Mice were challenged with Renca-vIII(+) cells after
immunization for five times, and the tumor progression
was observed. By day 21 after tumor implantation, all
mice in HBcAg and PBS groups developed significant
tumors. In mice immunized with fusion protein, three of
ten mice failed to develop tumor and all survived at the
end of the research. The mean size and weight of tumors
in each group were monitored every three days. Results
were shown in Figure 12 and 13. These results demon-
strated that immunization with EGFRvIII-HBcAg fusion
protein resulted in protective effect against tumor.
Figure 5
SDS-PAGE analysis of recombinant protein. Lane 1:
protein molecular weight marker; Lane2: negative control:
recombinant plasmid Pep3-HBcAg/pET28a (+) transformed
E. coli BL21 cells not induced by IPTG; Lane 3: HBcAg/
pET28a (+) transformed E. coli BL21 cells induced by IPTG
Lane 4, 5: supernatant and sediment of recombinant plasmid
Pep3-HBcAg/pET28a (+) induced by IPTG; Lane 6: purified
recombinant fusion protein.
Figure 6
Western blot analysis. Lane 1: Western blot of pET28a (+);
Lane 2: Western blot of EGFRvIII-HBcAg fusion protein using
EGFRvIII-specific monoclonal antibody; Lane 3: protein marker.
Figure 7
Time course of immunization response. Mice
immunized with fusion protein produced specific antibody
responses, which increased significantly from week 5 and
peaked at week 7. However, no obvious antibody response
was detected in mice immunized with HBcAg or PBS.
Figure 8
Frenquency of IFN-g-secreting cells in splenocytes
from mice innunized with fusion protein was much
higher than that in HBcAg or PBS.
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Discussions
A major obstacle for efficient antitumor therapy is lack of
specificity. The variant EGF receptor, EGFRvIII, is tumor
specific, and is correlated with tumor progression and
poor survival [11-14]. It has been reported that Pep-3
peptide can generate EGFRvIII-specific antitumor
immune responses [15-18]. So, EGFRvIII is a potential
therapeutic target. Genetically engineering vaccine is
simple and relatively inexpensive to prepare in large
quantities. In this study, we designed recombinant
plasmids with insertion of EGFRvIII Pep-3 epitope into
the immunodominant e1 loop of the HBcAg and
observed adequate expression of recombinant fusion
proteins in E. coli. This fusion protein could selectively
combine with EGFRvIII-specific antibody, which showed
fusion of HBcAg and EGFRvIII epitopes did not affect the
antigenicity of EGFRvIII sequence.
Using ELISA, we found that the titers of anti-fusion
protein antibody in mice immunized with fusion protein
were much higher than that in HBcAg or PBS group. We
further observed that fusion protein resulted in a high
frequency of IFN-g-secreting lymphocytes, which sug-
gests that the IFN-g response is tumor-specific and Th1-
type dominant immune response. Next analysis showed
CD4+T cells rather than CD8+T cells were associated
with the production of IFN-g. Using Renca-vIII(+) cell as
Figure 9
Frequency of IFN-g-secreting cells in CD4- depleted
splenocytes was dramatically lower than
CD8- depleted splenocytes.
Figure 10
Using Renca-vIII(+) cells as specific stimulator,
cytolytic activity against Renca-vIII(+) cells was
observed in splenocytes immunized with fusion
protein.
Figure 11
Using Renca vIII(-) cells as specific stimulator cells.
cytolytic activity against Renca-vIII(+) cells was not obvious
in splenocytes immunized with fusion protein.
Figure 12
Tumor growth curve of BALB/c mice immunized
with fusion protein, HBcAg or PBS. Among the three
groups, immunized with fusion protein showed resistance to
tumor development.
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specific stimulator, we observed remarkable cytotoxic
activity in splenocytes from mice immunized with fusion
protein, which further indicates that anti-tumor effect of
fusion protein is EGFRvIII-specific. In vivo study,
immunization with fusion protein can better protect
mice from EGFRvIII(+) tumor cell challenge.
It has been confirmed that CD4+ and CD8+ T lymphocytes
play important roles in induction of anti-tumor immune. In
this study, EGFRvIII-HBcAg fusion protein induced anti-
tumor immunity, and this immunity was mainly mediated
by CD4+ T cells. There are two possible explanations for the
effect mechanism of CD4+ T lymphocytes. One is the
requirement of CD4+ T cells for the induction of natural
killer cells and inhibition of tumor through IFN-g produc-
tion by T cells and IFN-g receptor expression[19,20].
Another possible explanation is CD4+ T cell-mediated
antibody production[21]. Patel D tested the anti-EGFR
monoclonal antibody cetuximab for its interaction with
EGFRvIII, andhe found cetuximab could bind specifically to
the EGFRvIII on the cell surface, thus leading to at least 50%
of the cetuximab-EGFRvIII complex internalized from cell
surface. This internalization led to a reduction in phos-
phorylated EGFRvIII in transfected cells, thus resulting in
40-50% inhibition of cell proliferation[22]. So, we presume
that EGFRvIII-HBcAg fusion protein induces mainly
humoral response andproduces antigen-specific antibodies.
The antibodies combined with EGFRvIII on the surface of
tumor cells may result in receptor down-regulation and
block tyrosine kinase activity, which inhibit the growth of
tumor or protect body against EGFRvIII(+) tumor challenge.
In summary, we successfully prepared the EGFRvIII-
HBcAg fusion protein. Immunization of animals with
fusion protein stimulates an Ag-specific humoral
response, and confers protective immunity to tumor
challenge of EGFRvIII(+) tumor cells. We hope our
approach will be helpful to the further research into a
viable practical tumor vaccine.
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